Welcome to our dedicated page for Nurix Therapeutics SEC filings (Ticker: NRIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Nurix Therapeutics, Inc. (Nasdaq: NRIX) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a clinical-stage biopharmaceutical issuer focused on targeted protein degradation medicines, Nurix uses its 10-K, 10-Q and 8-K reports to describe pipeline progress, financing activities, collaborations and governance matters.
Recent Form 8-K filings illustrate the types of information NRIX investors can monitor here. One 8-K details an underwriting agreement for a registered offering of common stock under a shelf registration statement, including intended uses of proceeds such as funding clinical development of the BTK degrader bexobrutideg in chronic lymphocytic leukemia, exploring autoimmune indications, expanding the research pipeline and supporting general corporate purposes. Other 8-Ks report on the initiation of the pivotal DAYBreak Phase 2 study of bexobrutideg in relapsed or refractory CLL/SLL, updated clinical data for NX-1607, and changes to the board of directors and committee roles.
Through this page, users can review current and historical SEC documents related to Nurix’s common stock listed on the Nasdaq Global Market under the symbol NRIX. Filings may cover topics such as results of operations, equity offerings, clinical development milestones, collaboration agreements with partners like Gilead, Sanofi and Pfizer, and appointments or resignations of directors and officers.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand material events without reading every page. Real-time updates from EDGAR ensure that new 8-K, 10-Q, 10-K and other forms appear promptly, while dedicated sections make it easier to locate items related to capital raises, clinical trial disclosures or governance changes. For those tracking insider activity, Form 4 and related ownership filings can also be accessed to see how Nurix’s insiders transact in NRIX shares.
Nurix Therapeutics, Inc. reported higher losses for the quarter ended February 28, 2026 as it invested heavily in its targeted protein degradation pipeline. Collaboration revenue fell to $6.3 million from $18.5 million a year earlier, mainly reflecting timing of milestone and research activities.
Research and development expenses rose to $84.1 million from $69.7 million, driving a net loss of $87.2 million versus $56.4 million in the prior-year quarter. Operating cash outflow was $71.9 million, while cash, cash equivalents and marketable securities totaled $540.7 million, which management believes is sufficient for at least 12 months of operations.
The company continues to advance clinical programs including BTK degraders bexobrutideg (NX‑5948) and zelebrudomide (NX‑2127), and CBL‑B inhibitor NX‑1607. It maintains sizable collaboration potential with Gilead, Sanofi and Pfizer and access to equity financing through at-the-market and registered direct offerings.
Nurix Therapeutics reported fiscal first quarter 2026 results and updated progress across its clinical pipeline. Revenue was $6.3 million, down from $18.5 million a year earlier as certain Sanofi collaboration research terms ended. Research and development expenses rose to $84.1 million and general and administrative costs increased to $14.6 million, reflecting expanded clinical activity.
Net loss widened to $87.2 million, or ($0.79) per share, compared with ($0.67) per share in the prior-year quarter. Nurix ended the quarter with $540.7 million in cash, cash equivalents and marketable securities. The company highlighted ongoing Phase 2 and planned Phase 3 studies of bexobrutideg in relapsed/refractory chronic lymphocytic leukemia, additional oncology programs, and partnered degraders with Gilead and Sanofi.
Nurix Therapeutics Chief Legal Officer Christine Ring sold 8,148 shares of common stock in an open-market transaction. The weighted average sale price was $15.2367 per share, with individual trades ranging from $15.00 to $15.43. Following the sale, she directly holds 26,453 Nurix shares. The transaction was executed under a previously adopted Rule 10b5-1 trading plan, indicating it was pre-scheduled rather than a discretionary trade.
Morgan Stanley Smith Barney LLC Executive Financial Services submitted a Rule 144 notice listing 8,148 shares of Common stock tied to Restricted Stock Units dated 05/02/2022 for resale. The filing also lists recent 10b5-1 sales by Christine Ring on 03/02/2026, 02/09/2026 and 01/20/2026 showing multiple executed transactions and dollar amounts.
Nurix Therapeutics Inc Schedule 13G/A: The Vanguard Group filed an amendment stating it beneficially owns 0 shares (0%) of Nurix common stock following an internal realignment. The filing cites SEC Release No. 34-39538 (January 12, 1998) and says certain Vanguard subsidiaries will report separately after the realignment.
The filing lists Vanguard's address as 100 Vanguard Blvd., Malvern, PA and is signed by Ashley Grim, Head of Global Fund Administration, dated 03/27/2026. The statement explains Vanguard no longer is deemed to have beneficial ownership of securities held by the disaggregated subsidiaries.
Nurix Therapeutics has issued its 2026 proxy for a virtual annual meeting on May 15, where stockholders will vote on electing three Class III directors, ratifying PricewaterhouseCoopers as auditor, and a non-binding say-on-pay proposal. The CEO’s letter highlights strong 2025 pipeline progress, led by BTK degrader bexobrutideg, which showed an 83.0% objective response rate and 22.1-month median progression-free survival in heavily pretreated CLL, and a 75.0% response rate in Waldenström macroglobulinemia. Nurix ended fiscal 2025 with $592.9 million in cash, cash equivalents and marketable securities and completed a $250.0 million underwritten offering, while recognizing $84.0 million in collaboration revenue and remaining eligible for up to $6.1 billion in future milestones and royalties.
Nurix Therapeutics, Inc. updated its existing “at the market” stock offering program by entering into Amendment No. 3 to its equity distribution agreement with Piper Sandler. Under this amendment, the company may, from time to time, offer and sell through Piper Sandler up to $413.65 million of its common stock under its automatic shelf registration statement and related prospectus documents.
Nurix Therapeutics amends its prospectus supplement to increase the at-the-market offering capacity to $413,650,000. The amendment raises the aggregate dollar amount of common stock available for sale under an amended Equity Distribution Agreement with Piper Sandler to $413.65 million.
As context, the company states it has sold 4,634,393 shares for gross proceeds of approximately $113.65 million under the agreement and had 101,807,484 shares outstanding as of November 30, 2025. Sales under the program may occur from time to time at market prices; Piper Sandler may receive commissions up to 3.0%.
Nurix Therapeutics, Inc. Chief Legal Officer Christine Ring sold 8,148 shares of common stock in an open-market transaction on March 2, 2026. The shares were sold at a weighted average price of $15.4385 per share under a previously adopted Rule 10b5-1 trading plan. Following this sale, she directly holds 34,601 Nurix shares.